Notification of Preliminary Results and AGM

Beximco Pharmaceuticals PLC

29 October 2026

 

 29 October 2026

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

BEXIMCO PHARMACEUTICALS PLC.

Notification of Preliminary Results and Annual General Meeting

Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces information for shareholders of the Company that the Board of Directors decided at their meeting held on 28 October 2026. Please see further details as follows:

1.	To recommend the approval of the Financial statements for the year ended 30 June 2026	The Audited financial statements for the year ended 30 June 2026 have been approved. The full accounts are expected to be announced by 09 November 2026.
2.	Date, Time, Venue/Mode of 50th Annual General Meeting ("AGM") of the Company for the year ended 30 June 2026	The convening of the 50th Annual General Meeting (AGM) of the Company, relating to the financial year 2025-26, is dependent upon the holding of the 49th AGM, relating to the financial year 2024-25. An application seeking condonation of the delay in holding the 49th AGM (Company Matter No. 1112 of 2026) is pending before the Hon'ble High Court Division of the Supreme Court of Bangladesh. The hearing has been concluded, and the Court's judgment is scheduled to be delivered on 1 November 2026. Accordingly, the date, time and other arrangements for the 49th and 50th AGMs will be communicated to the shareholders in due course, following the Court's judgment and in accordance with applicable legal and regulatory requirements.
3.	Proposed Dividend for the year ended 30 June 2026	60% Cash Dividend (i.e. Tk. 6.00 per Share)
4.	Record date	19 November 2026

Comparative Financial Disclosures:

Beximco Pharmaceuticals PLC. and its Subsidiaries (Consolidated)

Particulars	Year ended  30 June 2026	Year ended  30 June 2025
	Taka	Taka
Net profit after tax	9,160,840,056	6,998,869,709
Net assets value (NAV)	62,091,204,932	53,107,137,101
Earnings per share (EPS)	20.17	15.56
Net assets value per share (NAVPS)	139.18	119.04
Net operating cash flows per share (NOCFPS)	21.33	16.19

Beximco Pharmaceuticals PLC. (Stand-alone)

Particulars	Year ended  30 June 2026	Year ended  30 June 2025
	Taka	Taka
Net profit after tax	8,524,679,176	6,712,564,301
Net assets value (NAV)	60,831,922,377	52,320,598,446
Earnings per share (EPS)	19.11	15.05
Net assets value per share (NAVPS)	136.36	117.28
Net operating cash flows per share (NOCFPS)	19.33	15.05

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

S M Rabbur Reza, Chief Operating Officer

Tel: [phone], Ext. 20111

Mohammad Ali Nawaz, Chief Financial Officer

Tel: [phone], Ext. 20030

Mohammad Asad Ullah, FCS

Executive Director & Company Secretary

Tel: [phone], Ext. 10140

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: [phone] / 3555

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: [phone]

FTI Consulting

Simon Conway / Sam Purewal / Lucy Molloy

Tel: [phone]

Notes to Editors

About Beximco Pharmaceuticals PLC.

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.

 

END